{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:33:19Z","timestamp":1793313199645,"version":"4.5.0"},"reference-count":189,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Child and Adolescent Psychiatric Clinics of North America"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1016\/j.chc.2005.08.007","type":"journal-article","created":{"date-parts":[[2007,1,10]],"date-time":"2007-01-10T10:10:36Z","timestamp":1168423836000},"page":"177-206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":164,"title":["Recognizing and Monitoring Adverse Events of Second-Generation Antipsychotics in Children and Adolescents"],"prefix":"10.1016","volume":"15","author":[{"given":"Christoph U.","family":"Correll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie B.","family":"Penzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh H.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahir","family":"Mughal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Javed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren","family":"Carbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.chc.2005.08.007_bib1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1089\/cap.2004.14.372","article-title":"Second-generation antipsychotic medications in children and adolescents","volume":"14","author":"Cheng-Shannon","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"10.1016\/j.chc.2005.08.007_bib2","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.chc.2004.04.007","article-title":"A review of the growing evidence base for pediatric psychopharmacology","volume":"13","author":"Pappadopulos","year":"2004","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"issue":"8","key":"10.1016\/j.chc.2005.08.007_bib3","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/archpedi.158.8.753","article-title":"New users of antipsychotic medications among children enrolled in TennCare","volume":"158","author":"Cooper","year":"2004","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"1","key":"10.1016\/j.chc.2005.08.007_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/archpedi.157.1.17","article-title":"Psychotropic practice patterns for youth: a 10-year perspective","volume":"157","author":"Zito","year":"2003","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"3","key":"10.1016\/j.chc.2005.08.007_bib5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1089\/104454602760386905","article-title":"Trends in antipsychotic use in a Texas Medicaid population of children and adolescents: 1996 to 2000","volume":"12","author":"Patel","year":"2002","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"10.1016\/j.chc.2005.08.007_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/cap.2005.15.57","article-title":"Current prescribing patterns in outpatient child and adolescent psychiatric practice in central New York","volume":"15","author":"Staller","year":"2005","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"10.1016\/j.chc.2005.08.007_bib7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1089\/104454604773840517","article-title":"Atypical antipsychotic use in a state hospital inpatient adolescent population","volume":"14","author":"Kelly","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1016\/j.chc.2005.08.007_bib8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1023\/B:COMH.0000022731.65054.3e","article-title":"Psychotropic medications prescribing patterns for children and adolescents in New York's public mental health system","volume":"40","author":"Lyons","year":"2004","journal-title":"Community Ment Health J"},{"issue":"1","key":"10.1016\/j.chc.2005.08.007_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00023210-200216010-00003","article-title":"Effects of newer antipsychotics on extrapyramidal function","volume":"16","author":"Tarsy","year":"2002","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.chc.2005.08.007_bib10","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies","volume":"161","author":"Correll","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"6","key":"10.1016\/j.chc.2005.08.007_bib11","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.60.6.553","article-title":"A meta-analysis of the efficacy of second-generation antipsychotics","volume":"60","author":"Davis","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.chc.2005.08.007_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(98)00105-4","article-title":"Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials","volume":"35","author":"Leucht","year":"1999","journal-title":"Schizophr Res"},{"issue":"11","key":"10.1016\/j.chc.2005.08.007_bib13","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S0006-3223(01)01256-2","article-title":"Broad therapeutic uses of atypical antipsychotic medications","volume":"50","author":"Buckley","year":"2001","journal-title":"Biol Psychiatry"},{"issue":"5","key":"10.1016\/j.chc.2005.08.007_bib14","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1176\/appi.ps.54.5.719","article-title":"Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program","volume":"54","author":"Menzin","year":"2003","journal-title":"Psychiatr Serv"},{"issue":"1","key":"10.1016\/j.chc.2005.08.007_bib15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1176\/appi.ajp.159.1.103","article-title":"Antipsychotic medication adherence: is there a difference between typical and atypical agents?","volume":"159","author":"Dolder","year":"2002","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.chc.2005.08.007_bib16","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.chc.2005.08.007_bib17","series-title":"Practitioner's guide to psychoactive drugs for children and adolescents","first-page":"23","article-title":"Pharmacology","author":"Paxton","year":"1993"},{"issue":"4","key":"10.1016\/j.chc.2005.08.007_bib18","first-page":"401","article-title":"Psychopharmacology of children and adolescents: pharmacokinetics and relationships of plasma\/serum levels to response","volume":"27","author":"Geller","year":"1991","journal-title":"Psychopharmacol Bull"},{"issue":"12","key":"10.1016\/j.chc.2005.08.007_bib19","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/00004583-200212000-00015","article-title":"Effects of development on olanzapine-associated adverse events","volume":"41","author":"Woods","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"10.1016\/j.chc.2005.08.007_bib20","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/01.CHI.0000046841.56865.37","article-title":"Review of safety assessment methods used in pediatric psychopharmacology","volume":"42","author":"Greenhill","year":"2003","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"19","key":"10.1016\/j.chc.2005.08.007_bib21","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.chc.2005.08.007_bib22","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/archpedi.157.8.821","article-title":"Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988\u20131994","volume":"157","author":"Cook","year":"2003","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"4","key":"10.1016\/j.chc.2005.08.007_bib23","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jpeds.2004.06.044","article-title":"Waist circumference percentiles in nationally representative samples of African-American, European-American, and Mexican-American children and adolescents","volume":"145","author":"Fernandez","year":"2004","journal-title":"J Pediatr"},{"key":"10.1016\/j.chc.2005.08.007_bib24","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1542\/peds.114.S2.555","article-title":"The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents","volume":"114","year":"2004","journal-title":"Pediatrics"},{"issue":"23","key":"10.1016\/j.chc.2005.08.007_bib25","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1056\/NEJMoa031049","article-title":"Obesity and the metabolic syndrome in children and adolescents","volume":"350","author":"Weiss","year":"2004","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.chc.2005.08.007_bib26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4088\/JCP.v60n0402","article-title":"The distribution of body mass index among individuals with and without schizophrenia","volume":"60","author":"Allison","year":"1999","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.chc.2005.08.007_bib27","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00213-004-1949-9","article-title":"Pharmacogenetics of antipsychotic-induced weight gain","volume":"174","author":"Correll","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"issue":"17","key":"10.1016\/j.chc.2005.08.007_bib28","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1001\/jama.290.17.2277","article-title":"Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study","volume":"290","author":"Raitakari","year":"2003","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.chc.2005.08.007_bib29","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1001\/jama.290.17.2271","article-title":"Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study","volume":"290","author":"Li","year":"2003","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.chc.2005.08.007_bib30","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM199211053271904","article-title":"Long-term morbidity and mortality of overweight adolescents. A follow-up of the Harvard Growth Study of 1922 to 1935","volume":"327","author":"Must","year":"1992","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.chc.2005.08.007_bib31","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1176\/appi.ps.54.4.565","article-title":"The impact of weight gain on quality of life among persons with schizophrenia","volume":"54","author":"Allison","year":"2003","journal-title":"Psychiatr Serv"},{"issue":"1\u20132","key":"10.1016\/j.chc.2005.08.007_bib32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0920-9964(02)00441-3","article-title":"Body mass index and quality of life in community-dwelling patients with schizophrenia","volume":"62","author":"Strassnig","year":"2003","journal-title":"Schizophr Res"},{"issue":"Suppl 21","key":"10.1016\/j.chc.2005.08.007_bib33","first-page":"25","article-title":"Adherence to antipsychotic medications","volume":"60","author":"Perkins","year":"1999","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2005.08.007_bib34","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(02)00498-X","article-title":"Obesity as a risk factor for antipsychotic noncompliance","volume":"66","author":"Weiden","year":"2004","journal-title":"Schizophr Res"},{"issue":"11","key":"10.1016\/j.chc.2005.08.007_bib35","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.chc.2005.08.007_bib36","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/01.jcp.0000130558.86125.5b","article-title":"A comparison of risperidone-induced weight gain across the age span","volume":"24","author":"Safer","year":"2004","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.chc.2005.08.007_bib37","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00004583-200203000-00014","article-title":"Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study","volume":"41","author":"Ratzoni","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.chc.2005.08.007_bib38","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-9964(03)00050-1","article-title":"Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials","volume":"61","author":"Marder","year":"2003","journal-title":"Schizophr Res"},{"issue":"Suppl 8","key":"10.1016\/j.chc.2005.08.007_bib39","first-page":"36","article-title":"Body composition changes associated with second-generation antipsychotics","volume":"57","author":"Correll","year":"2005","journal-title":"Biol Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2005.08.007_bib40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00148581-200406010-00003","article-title":"Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management","volume":"6","author":"Stigler","year":"2004","journal-title":"Paediatr Drugs"},{"issue":"2","key":"10.1016\/j.chc.2005.08.007_bib41","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/1044546041649020","article-title":"Risperidone effects in the presence\/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ","volume":"14","author":"Aman","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"10.1016\/j.chc.2005.08.007_bib42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/sj.npp.1300327","article-title":"A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial","volume":"29","author":"Sikich","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.chc.2005.08.007_bib43","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1176\/appi.ajp.162.6.1217","article-title":"Cost-effective screening for metabolic syndrome in patients treated with second-generation antipsychotic medications","volume":"162","author":"Straker","year":"2005","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.chc.2005.08.007_bib44","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4088\/JCP.v65n0417","article-title":"Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics","volume":"65","author":"Almeras","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"10.1016\/j.chc.2005.08.007_bib45","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/070674370404901106","article-title":"Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome","volume":"49","author":"Cohn","year":"2004","journal-title":"Can J Psychiatry"},{"issue":"4","key":"10.1016\/j.chc.2005.08.007_bib46","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1399-5618.2004.00126.x","article-title":"The prevalence of the metabolic syndrome in patients with schizoaffective disorder\u2013bipolar subtype","volume":"6","author":"Basu","year":"2004","journal-title":"Bipolar Disord"},{"issue":"5","key":"10.1016\/j.chc.2005.08.007_bib47","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4088\/JCP.v64n0513","article-title":"Metabolic syndrome in patients with schizophrenia","volume":"64","author":"Heiskanen","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"10.1016\/j.chc.2005.08.007_bib48","doi-asserted-by":"crossref","first-page":"856","DOI":"10.4088\/JCP.v63n1002","article-title":"The effects of novel antipsychotics on glucose and lipid levels","volume":"63","author":"Wirshing","year":"2002","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"10.1016\/j.chc.2005.08.007_bib49","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archpsyc.59.11.1021","article-title":"An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients","volume":"59","author":"Koro","year":"2002","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"10.1016\/j.chc.2005.08.007_bib50","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4088\/JCP.v63n0509","article-title":"A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year","volume":"63","author":"Meyer","year":"2002","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.chc.2005.08.007_bib51","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/00004583-200205000-00004","article-title":"Quetiapine-associated hyperglycemia and hypertriglyceridemia","volume":"41","author":"Domon","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"10.1016\/j.chc.2005.08.007_bib52","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/10445460152595603","article-title":"Hyperglycemia and hypertriglyceridemia secondary to olanzapine","volume":"11","author":"Domon","year":"2001","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1016\/j.chc.2005.08.007_bib53","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00004583-200102000-00006","article-title":"Olanzapine and hypertriglyceridemia","volume":"40","author":"Nguyen","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"10.1016\/j.chc.2005.08.007_bib54","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00787-002-0255-5","article-title":"Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study","volume":"11","author":"Martin","year":"2002","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"Suppl 8","key":"10.1016\/j.chc.2005.08.007_bib55","first-page":"36","article-title":"Development of insulin resistance in antipsychotic-na\u00efve youngsters treated with novel antipsychotics","volume":"57","author":"Correll","year":"2005","journal-title":"Biol Psychiatry"},{"issue":"12","key":"10.1016\/j.chc.2005.08.007_bib56","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.clinthera.2004.12.003","article-title":"Metabolic risk during antipsychotic treatment","volume":"26","author":"Newcomer","year":"2004","journal-title":"Clin Ther"},{"issue":"11","key":"10.1016\/j.chc.2005.08.007_bib57","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1056\/NEJMoa012578","article-title":"Prevalence of impaired glucose tolerance among children and adolescents with marked obesity","volume":"346","author":"Sinha","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.chc.2005.08.007_bib58","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archpsyc.62.1.19","article-title":"Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents","volume":"62","author":"Henderson","year":"2005","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"10.1016\/j.chc.2005.08.007_bib59","doi-asserted-by":"crossref","first-page":"504","DOI":"10.4088\/JCP.v66n0414","article-title":"Atypical antipsychotics and glucose homeostasis","volume":"66","author":"Bergman","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.chc.2005.08.007_bib60","doi-asserted-by":"crossref","first-page":"862","DOI":"10.2337\/diabetes.54.3.862","article-title":"Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs","volume":"54","author":"Ader","year":"2005","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.chc.2005.08.007_bib61","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1468-1331.2004.00899.x","article-title":"Antiepileptic drugs alter reproductive endocrine hormones in men with epilepsy","volume":"12","author":"Roste","year":"2005","journal-title":"Eur J Neurol"},{"issue":"4","key":"10.1016\/j.chc.2005.08.007_bib62","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1212\/01.WNL.0000048209.07526.86","article-title":"Fasting serum insulin and lipid levels in men with epilepsy","volume":"60","author":"Pylvanen","year":"2003","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.chc.2005.08.007_bib63","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s00415-002-0731-3","article-title":"Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women","volume":"249","author":"Luef","year":"2002","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.chc.2005.08.007_bib64","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1089\/104454602760386914","article-title":"Can diabetes mellitus be induced by medication?","volume":"12","author":"Saito","year":"2002","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"10.1016\/j.chc.2005.08.007_bib65","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1089\/cap.2004.14.612","article-title":"Olanzapine-induced diabetes in a seven-year-old boy","volume":"14","author":"Courvoisie","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1016\/j.chc.2005.08.007_bib66","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1542\/peds.113.2.421","article-title":"Risperidone-associated diabetes mellitus in children","volume":"113","author":"Koller","year":"2004","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.chc.2005.08.007_bib67","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1067\/mpd.2001.114016","article-title":"Diabetic ketoacidosis associated with olanzapine in an adolescent patient","volume":"138","author":"Selva","year":"2001","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.chc.2005.08.007_bib68","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1089\/104454603321666234","article-title":"Hyperglycemia from olanzapine treatment in adolescents","volume":"13","author":"Bloch","year":"2003","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"Suppl 8","key":"10.1016\/j.chc.2005.08.007_bib69","first-page":"36","article-title":"New-onset dyslipidemia in antipsychotic-na\u00efve youngsters treated with atypical antipsychotics","volume":"57","author":"Correll","year":"2005","journal-title":"Biol Psychiatry"},{"issue":"6","key":"10.1016\/j.chc.2005.08.007_bib70","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1176\/appi.ajp.161.6.1125","article-title":"Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data","volume":"161","author":"Martin","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.chc.2005.08.007_bib71","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1089\/cap.2004.14.350","article-title":"A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents","volume":"14","author":"Saito","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"11","key":"10.1016\/j.chc.2005.08.007_bib72","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.4088\/JCP.v64n1113","article-title":"Prolactin levels during long-term risperidone treatment in children and adolescents","volume":"64","author":"Findling","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"10.1016\/j.chc.2005.08.007_bib73","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.4088\/JCP.v64n0909","article-title":"A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone","volume":"64","author":"Masi","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.chc.2005.08.007_bib74","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/cap.1999.9.239","article-title":"Elevated prolactin in pediatric patients on typical and atypical antipsychotics","volume":"9","author":"Wudarsky","year":"1999","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"10.1016\/j.chc.2005.08.007_bib75","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/syn.890010503","article-title":"Human brain dopamine receptors in children and aging adults","volume":"1","author":"Seeman","year":"1987","journal-title":"Synapse"},{"issue":"Suppl 2","key":"10.1016\/j.chc.2005.08.007_bib76","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0306-4530(02)00128-2","article-title":"Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials","volume":"28","author":"Kinon","year":"2003","journal-title":"Psychoneuroendocrinology"},{"issue":"2","key":"10.1016\/j.chc.2005.08.007_bib77","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/104454602760219126","article-title":"Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine","volume":"12","author":"Alfaro","year":"2002","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"10.1016\/j.chc.2005.08.007_bib78","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1089\/cap.2004.14.359","article-title":"The effect of atypical antipsychotic agents on prolactin levels in children and adolescents","volume":"14","author":"Pappagallo","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"10.1016\/j.chc.2005.08.007_bib79","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1176\/appi.ajp.161.4.677","article-title":"Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ","volume":"161","author":"Findling","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.chc.2005.08.007_bib80","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1089\/104454601317261564","article-title":"Prolactin levels in young children with pervasive developmental disorders during risperidone treatment","volume":"11","author":"Masi","year":"2001","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"8","key":"10.1016\/j.chc.2005.08.007_bib81","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1176\/appi.ajp.159.8.1337","article-title":"Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence","volume":"159","author":"Aman","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.chc.2005.08.007_bib82","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/00004583-200209000-00002","article-title":"Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs","volume":"41","author":"Snyder","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"10.1016\/j.chc.2005.08.007_bib83","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00004583-200003000-00010","article-title":"Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study","volume":"39","author":"Sallee","year":"2000","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"10.1016\/j.chc.2005.08.007_bib84","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/104454601317261591","article-title":"A study of quetiapine: efficacy and tolerability in psychotic adolescents","volume":"11","author":"Shaw","year":"2001","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"8","key":"10.1016\/j.chc.2005.08.007_bib85","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1176\/appi.ajp.161.8.1334","article-title":"Physical health monitoring of patients with schizophrenia","volume":"161","author":"Marder","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2005.08.007_bib86","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/01.chi.0000145805.24274.09","article-title":"Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients","volume":"44","author":"Croonenberghs","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"10.1016\/j.chc.2005.08.007_bib87","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1542\/peds.110.3.e34","article-title":"Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs","volume":"110","author":"Turgay","year":"2002","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.chc.2005.08.007_bib88","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1176\/appi.ajp.161.5.918","article-title":"Growth and sexual maturation during long-term treatment with risperidone","volume":"161","author":"Dunbar","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"6","key":"10.1016\/j.chc.2005.08.007_bib89","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1177\/070674379804300608","article-title":"Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms","volume":"43","author":"Lewis","year":"1998","journal-title":"Can J Psychiatry"},{"issue":"14","key":"10.1016\/j.chc.2005.08.007_bib90","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00002018-200427140-00005","article-title":"Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents","volume":"27","author":"Toren","year":"2004","journal-title":"Drug Saf"},{"issue":"6","key":"10.1016\/j.chc.2005.08.007_bib91","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/01.jcp.0000096244.29231.e1","article-title":"Extrapyramidal symptoms in children on atypical antipsychotic drugs","volume":"23","author":"Sathpathy","year":"2003","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.chc.2005.08.007_bib92","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/00004583-199901000-00009","article-title":"Movement disorders in children with developmental disabilities taking risperidone","volume":"38","author":"Demb","year":"1999","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"10.1016\/j.chc.2005.08.007_bib93","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/cap.1996.6.251","article-title":"Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study","volume":"6","author":"Grcevich","year":"1996","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"10.1016\/j.chc.2005.08.007_bib94","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1089\/cap.1995.5.49","article-title":"Risperidone treatment of children and adolescents: increased risk for extrapyramidal side effects?","volume":"5","author":"Mandoki","year":"1995","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"10.1016\/j.chc.2005.08.007_bib95","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/00004583-199705000-00020","article-title":"Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study","volume":"36","author":"McDougle","year":"1997","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"10.1016\/j.chc.2005.08.007_bib96","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/cap.1997.7.167","article-title":"Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up","volume":"7","author":"Perry","year":"1997","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"6","key":"10.1016\/j.chc.2005.08.007_bib97","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1542\/peds.2004-1268","article-title":"Severe extrapyramidal symptoms in a 3-year-old boy after accidental ingestion of the new antipsychotic drug aripiprazole","volume":"114","author":"Schonberger","year":"2004","journal-title":"Pediatrics"},{"issue":"11","key":"10.1016\/j.chc.2005.08.007_bib98","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1097\/01.chi.0000095540.18151.b0","article-title":"Aripiprazole and extrapyramidal symptoms","volume":"42","author":"Lindsey","year":"2003","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"11","key":"10.1016\/j.chc.2005.08.007_bib99","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/00005053-198811000-00006","article-title":"Increased extrapyramidal symptoms with addition of lithium to neuroleptics","volume":"176","author":"Addonizio","year":"1988","journal-title":"J Nerv Ment Dis"},{"issue":"2","key":"10.1016\/j.chc.2005.08.007_bib100","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00004583-199802000-00016","article-title":"Case series: spectrum of neuroleptic-induced movement disorders and extrapyramidal side effects in childhood-onset schizophrenia","volume":"37","author":"Kumra","year":"1998","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"10.1016\/j.chc.2005.08.007_bib101","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/00004583-199706000-00022","article-title":"Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study","volume":"36","author":"Campbell","year":"1997","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"12","key":"10.1016\/j.chc.2005.08.007_bib102","doi-asserted-by":"crossref","first-page":"967","DOI":"10.4088\/JCP.v62n1209","article-title":"Neuroleptic-related dyskinesias in children and adolescents","volume":"62","author":"Connor","year":"2001","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.chc.2005.08.007_bib103","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/00004583-200202000-00007","article-title":"Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness","volume":"41","author":"Malone","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"11","key":"10.1016\/j.chc.2005.08.007_bib104","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1097\/00004583-199611000-00006","article-title":"Risperidone and tardive dyskinesia","volume":"35","author":"Feeney","year":"1996","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"7","key":"10.1016\/j.chc.2005.08.007_bib105","doi-asserted-by":"crossref","first-page":"485","DOI":"10.4088\/JCP.v60n0711b","article-title":"Chorea and tardive dyskinesia in a patient taking risperidone","volume":"60","author":"Carroll","year":"1999","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.chc.2005.08.007_bib106","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1176\/appi.ajp.161.4.757-a","article-title":"Tardive dyskinesia in an autistic patient treated with risperidone","volume":"161","author":"Kwon","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"11","key":"10.1016\/j.chc.2005.08.007_bib107","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.4088\/JCP.v65n1115","article-title":"A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders","volume":"65","author":"Corson","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.chc.2005.08.007_bib108","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1089\/104454603322572633","article-title":"A 1-year open-label trial of olanzapine in school-age children with schizophrenia","volume":"13","author":"Ross","year":"2003","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"7","key":"10.1016\/j.chc.2005.08.007_bib109","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00702-004-0153-8","article-title":"Electrocardiographic safety profile and monitoring guidelines in pediatric psychopharmacology","volume":"111","author":"Blair","year":"2004","journal-title":"J Neural Transm"},{"issue":"11","key":"10.1016\/j.chc.2005.08.007_bib110","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1176\/appi.ajp.158.11.1774","article-title":"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death","volume":"158","author":"Glassman","year":"2001","journal-title":"Am J Psychiatry"},{"issue":"8","key":"10.1016\/j.chc.2005.08.007_bib111","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2165\/00128072-200103080-00006","article-title":"Sudden death related to selected tricyclic antidepressants in children: epidemiology, mechanisms and clinical implications","volume":"3","author":"Varley","year":"2001","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.chc.2005.08.007_bib112","first-page":"353","article-title":"An analysis of the time-relations of electrocardiograms","volume":"7","author":"Bazett","year":"1918","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.chc.2005.08.007_bib113","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1046\/j.1540-8167.2005.03520.x","article-title":"QT correction methods in children and adolescents","volume":"16","author":"Wernicke","year":"2005","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"2","key":"10.1016\/j.chc.2005.08.007_bib114","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1034\/j.1600-0447.2003.02078.x","article-title":"Antipsychotics and QT prolongation","volume":"107","author":"Taylor","year":"2003","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.chc.2005.08.007_bib115","series-title":"Ziprasidone [package insert]","year":"2002"},{"issue":"10","key":"10.1016\/j.chc.2005.08.007_bib116","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1517\/14656566.2.10.1655","article-title":"Ziprasidone: profile on safety","volume":"2","author":"Goodnick","year":"2001","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10.1016\/j.chc.2005.08.007_bib117","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/01.chi.0000145372.61239.bb","article-title":"Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study","volume":"44","author":"Blair","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"10.1016\/j.chc.2005.08.007_bib118","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/0269881105049042","article-title":"Sudden death in a patient with Tourette syndrome during a clinical trial of ziprasidone","volume":"19","author":"Scahill","year":"2005","journal-title":"J Psychopharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.chc.2005.08.007_bib119","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1055\/s-2004-828458","article-title":"[Risk of QTc prolongation due to combination of ziprasidone and quetiapine]","volume":"31","author":"Minov","year":"2004","journal-title":"Psychiatr Prax"},{"issue":"4","key":"10.1016\/j.chc.2005.08.007_bib120","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1191\/096032701678766778","article-title":"Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone","volume":"20","author":"Beelen","year":"2001","journal-title":"Hum Exp Toxicol"},{"issue":"1","key":"10.1016\/j.chc.2005.08.007_bib121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1744-859X-4-1","article-title":"QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy","volume":"4","author":"Sala","year":"2005","journal-title":"Ann Gen Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2005.08.007_bib122","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2710.2004.00616_1.x","article-title":"Myocarditis, pericarditis and cardiomyopathy in patients treated with clozapine","volume":"30","author":"Wehmeier","year":"2005","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"10.1016\/j.chc.2005.08.007_bib123","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2165\/00023210-200317050-00002","article-title":"Fatalities associated with therapeutic use and overdose of atypical antipsychotics","volume":"17","author":"Trenton","year":"2003","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.chc.2005.08.007_bib124","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1089\/1044546041649039","article-title":"Pericarditis and polyserositis as a side effect of clozapine in an adolescent girl","volume":"14","author":"Branik","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"10.1016\/j.chc.2005.08.007_bib125","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/00004714-200302000-00017","article-title":"Pancreatitis followed by pericardial effusion in an adolescent treated with clozapine","volume":"23","author":"Wehmeier","year":"2003","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.chc.2005.08.007_bib126","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1089\/1044546041648977","article-title":"Chart review for potential features of myocarditis, pericarditis, and cardiomyopathy in children and adolescents treated with clozapine","volume":"14","author":"Wehmeier","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.chc.2005.08.007_bib127","series-title":"Physicians' desk reference","year":"2004"},{"issue":"Suppl 18","key":"10.1016\/j.chc.2005.08.007_bib128","first-page":"47","article-title":"A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study","volume":"65","author":"McQuade","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"10.1016\/j.chc.2005.08.007_bib129","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.4088\/JCP.v65n1207","article-title":"Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial","volume":"65","author":"Addington","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.chc.2005.08.007_bib130","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1176\/appi.ajp.158.5.765","article-title":"A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder","volume":"158","author":"Conley","year":"2001","journal-title":"Am J Psychiatry"},{"issue":"8","key":"10.1016\/j.chc.2005.08.007_bib131","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1176\/appi.ajp.158.8.1305","article-title":"A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia","volume":"158","author":"Azorin","year":"2001","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2005.08.007_bib132","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archpsyc.60.1.82","article-title":"Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT)","volume":"60","author":"Meltzer","year":"2003","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"10.1016\/j.chc.2005.08.007_bib133","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/01.jcp.0000144887.66319.2f","article-title":"Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania","volume":"24","author":"Yatham","year":"2004","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"10.1016\/j.chc.2005.08.007_bib134","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1034\/j.1399-5618.2002.01204.x","article-title":"Quetiapine in the treatment of rapid cycling bipolar disorder","volume":"4","author":"Vieta","year":"2002","journal-title":"Bipolar Disord"},{"issue":"4","key":"10.1016\/j.chc.2005.08.007_bib135","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1089\/cap.2004.14.593","article-title":"The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review","volume":"14","author":"Barzman","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1016\/j.chc.2005.08.007_bib136","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1017\/S1092852900019489","article-title":"Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review","volume":"10","author":"Biederman","year":"2005","journal-title":"CNS Spectr"},{"issue":"8","key":"10.1016\/j.chc.2005.08.007_bib137","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/00004583-200208000-00010","article-title":"Case series: use of ziprasidone for maladaptive symptoms in youths with autism","volume":"41","author":"McDougle","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"10.1016\/j.chc.2005.08.007_bib138","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/104454603322572624","article-title":"Quetiapine treatment of children and adolescents with Tourette's disorder","volume":"13","author":"Mukaddes","year":"2003","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"10","key":"10.1016\/j.chc.2005.08.007_bib139","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1097\/00004583-200210000-00011","article-title":"A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania","volume":"41","author":"Delbello","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2005.08.007_bib140","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1089\/104454603321666216","article-title":"Long term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial","volume":"13","author":"McConville","year":"2003","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"9","key":"10.1016\/j.chc.2005.08.007_bib141","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.4088\/JCP.v65n0907","volume":"65","author":"Aman","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.chc.2005.08.007_bib142","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1542\/peds.2003-0264-F","article-title":"Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders","volume":"114","author":"Shea","year":"2004","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.chc.2005.08.007_bib143","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/10445460152595568","article-title":"A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder","volume":"11","author":"Frazier","year":"2001","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"10.1016\/j.chc.2005.08.007_bib144","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/104454604773840490","article-title":"The off-label use of clozapine in adolescents with bipolar disorder, intermittent explosive disorder, or posttraumatic stress disorder","volume":"14","author":"Kant","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1016\/j.chc.2005.08.007_bib145","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1089\/104454602760219135","article-title":"Clozapine in adolescent inpatients with acute mania","volume":"12","author":"Masi","year":"2002","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"12","key":"10.1016\/j.chc.2005.08.007_bib146","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1001\/archpsyc.1996.01830120020005","article-title":"Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison","volume":"53","author":"Kumra","year":"1996","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"10.1016\/j.chc.2005.08.007_bib147","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/00004583-199705000-00022","article-title":"Case study: risperidone-induced hepatotoxicity in pediatric patients","volume":"36","author":"Kumra","year":"1997","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"10.1016\/j.chc.2005.08.007_bib148","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1089\/cap.1999.9.93","article-title":"Risperidone-induced hepatotoxicity in children and adolescents? A chart review study","volume":"9","author":"Szigethy","year":"1999","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"10","key":"10.1016\/j.chc.2005.08.007_bib149","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/00004583-200310000-00014","article-title":"Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination","volume":"42","author":"Gonzalez-Heydrich","year":"2003","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.chc.2005.08.007_bib150","first-page":"S70","article-title":"Blood dyscrasias induced by psychotropic drugs","volume":"37","author":"Stubner","year":"2004","journal-title":"Pharmacopsychiatry"},{"issue":"Suppl B","key":"10.1016\/j.chc.2005.08.007_bib151","first-page":"137","article-title":"Agranulocytosis: incidence and risk factors","volume":"55","author":"Alvir","year":"1994","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.chc.2005.08.007_bib152","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM199307153290303","article-title":"Clozapine-induced agranulocytosis. Incidence and risk factors in the United States","volume":"329","author":"Alvir","year":"1993","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.chc.2005.08.007_bib153","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1176\/appi.ajp.157.6.1021","article-title":"Retreatment with clozapine after erythromycin-induced neutropenia","volume":"157","author":"Usiskin","year":"2000","journal-title":"Am J Psychiatry"},{"issue":"Suppl 8","key":"10.1016\/j.chc.2005.08.007_bib154","first-page":"14","article-title":"Review and management of clozapine side effects","volume":"61","author":"Miller","year":"2000","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.chc.2005.08.007_bib155","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1089\/104454603322572697","article-title":"Clozapine-induced neutropenia in children: management with lithium carbonate","volume":"13","author":"Sporn","year":"2003","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"10.1016\/j.chc.2005.08.007_bib156","doi-asserted-by":"crossref","first-page":"252","DOI":"10.4088\/JCP.v61n0403","article-title":"Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders","volume":"61","author":"McConville","year":"2000","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"10.1016\/j.chc.2005.08.007_bib157","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1345\/aph.1E054","article-title":"Thyroid function alterations following quetiapine initiation in a developmentally disabled adolescent","volume":"38","author":"Dobbs","year":"2004","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.chc.2005.08.007_bib158","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4088\/JCP.v66n0111","article-title":"Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine","volume":"66","author":"Kelly","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"10.1016\/j.chc.2005.08.007_bib159","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1358\/dot.2003.39.7.799445","article-title":"Antipsychotic medication and seizures: a review","volume":"39","author":"Hedges","year":"2003","journal-title":"Drugs Today (Barc)"},{"issue":"2","key":"10.1016\/j.chc.2005.08.007_bib160","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/1044546041649075","article-title":"No seizure exacerbation from risperidone in youth with comorbid epilepsy and psychiatric disorders: a case series","volume":"14","author":"Gonzalez-Heydrich","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"10.1016\/j.chc.2005.08.007_bib161","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1345\/aph.1A207","article-title":"New-onset seizure associated with quetiapine and olanzapine","volume":"36","author":"Hedges","year":"2002","journal-title":"Ann Pharmacother"},{"issue":"Suppl 4","key":"10.1016\/j.chc.2005.08.007_bib162","first-page":"12","article-title":"Movement disorders associated with atypical antipsychotic drugs","volume":"63","author":"Caroff","year":"2002","journal-title":"J Clin Psychiatry"},{"issue":"18","key":"10.1016\/j.chc.2005.08.007_bib163","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.2174\/1381612043384088","article-title":"Side effects of atypical antipsychotic drugs","volume":"10","author":"Ananth","year":"2004","journal-title":"Curr Pharm Des"},{"issue":"2","key":"10.1016\/j.chc.2005.08.007_bib164","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00004583-199902000-00018","article-title":"Neuroleptic malignant syndrome in children and adolescents","volume":"38","author":"Silva","year":"1999","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"10.1016\/j.chc.2005.08.007_bib165","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1089\/cap.2004.14.481","article-title":"Neuroleptic malignant syndrome in an adolescent after brief exposure to olanzapine","volume":"14","author":"Hanft","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"12","key":"10.1016\/j.chc.2005.08.007_bib166","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1097\/01.chi.0000142277.95052.94","article-title":"Aripiprazole and atypical neuroleptic malignant syndrome","volume":"43","author":"Spalding","year":"2004","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"10.1016\/j.chc.2005.08.007_bib167","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1081\/CLT-200035214","article-title":"Neuroleptic malignant syndrome in a child treated with an atypical antipsychotic","volume":"42","author":"Abu-Kishk","year":"2004","journal-title":"J Toxicol Clin Toxicol"},{"issue":"7","key":"10.1016\/j.chc.2005.08.007_bib168","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0149-2918(04)90182-8","article-title":"Neuroleptic malignant syndrome associated with ziprasidone in an adolescent","volume":"26","author":"Leibold","year":"2004","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.chc.2005.08.007_bib169","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1515\/IJAMH.2004.16.2.179","article-title":"Atypical neuroleptic malignant syndrome associated with risperidone treatment in two adolescents","volume":"16","author":"Zalsman","year":"2004","journal-title":"Int J Adolesc Med Health"},{"issue":"4","key":"10.1016\/j.chc.2005.08.007_bib170","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1089\/cap.2000.10.327","article-title":"Case study. Risperidone-induced neuroleptic malignant syndrome in an adolescent","volume":"10","author":"Robb","year":"2000","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"7\u20138","key":"10.1016\/j.chc.2005.08.007_bib171","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1177\/106002809603000713","article-title":"Risperidone-induced neuroleptic malignant syndrome","volume":"30","author":"Sharma","year":"1996","journal-title":"Ann Pharmacother"},{"issue":"5","key":"10.1016\/j.chc.2005.08.007_bib172","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/ajcn\/76.5.911","article-title":"Fructose, weight gain, and the insulin resistance syndrome","volume":"76","author":"Elliott","year":"2002","journal-title":"Am J Clin Nutr"},{"issue":"9255","key":"10.1016\/j.chc.2005.08.007_bib173","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(00)04041-1","article-title":"Relation between consumption of sugar-sweetened drinks and childhood obesity: a prospective, observational analysis","volume":"357","author":"Ludwig","year":"2001","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.chc.2005.08.007_bib174","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1753-4887.2001.tb07001.x","article-title":"Dietary fiber and weight regulation","volume":"59","author":"Howarth","year":"2001","journal-title":"Nutr Rev"},{"issue":"1","key":"10.1016\/j.chc.2005.08.007_bib175","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2337\/diacare.28.1.108","article-title":"Effects of exercise training on glucose homeostasis: the HERITAGE Family Study","volume":"28","author":"Boule","year":"2005","journal-title":"Diabetes Care"},{"issue":"5 Pt 2","key":"10.1016\/j.chc.2005.08.007_bib176","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jada.2005.02.031","article-title":"Behavioral interventions for obesity","volume":"105","author":"Berkel","year":"2005","journal-title":"J Am Diet Assoc"},{"key":"10.1016\/j.chc.2005.08.007_bib177","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1016\/j.chc.2005.08.007_bib178","first-page":"233","article-title":"The Extrapyramidal Symptom Rating Scale","volume":"7","author":"Chouinard","year":"1980","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.chc.2005.08.007_bib179","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.chc.2005.08.007_bib180","series-title":"ECDEU assessment manual for psychopharmacology. Publication #ABM 76\u2013338","year":"1976"},{"issue":"6","key":"10.1016\/j.chc.2005.08.007_bib181","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/01.CHI.0000046840.90931.36","article-title":"How can we improve the assessment of safety in child and adolescent psychopharmacology?","volume":"42","author":"Vitiello","year":"2003","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"10.1016\/j.chc.2005.08.007_bib182","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/01.CHI.0000046842.56865.EC","article-title":"Developing methodologies for monitoring long-term safety of psychotropic medications in children: report on the NIMH conference, September 25, 2000","volume":"42","author":"Greenhill","year":"2003","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"12","key":"10.1016\/j.chc.2005.08.007_bib183","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1097\/01.chi.0000142668.29191.13","article-title":"Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology","volume":"43","author":"Greenhill","year":"2004","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.chc.2005.08.007_bib184","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1542\/peds.112.2.424","article-title":"Prevention of pediatric overweight and obesity","volume":"112","year":"2003","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.chc.2005.08.007_bib185","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1161\/01.CIR.0000019555.61092.9E","article-title":"Cardiovascular health in childhood: a statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association","volume":"106","author":"Williams","year":"2002","journal-title":"Circulation"},{"issue":"4 Suppl","key":"10.1016\/j.chc.2005.08.007_bib186","first-page":"52S","article-title":"Tardive dyskinesia: prevalence, incidence, and risk factors","volume":"8","author":"Kane","year":"1988","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.chc.2005.08.007_bib187","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/00004583-200302000-00010","article-title":"A prospective, open-label trial of olanzapine in adolescents with schizophrenia","volume":"42","author":"Findling","year":"2003","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"10.1016\/j.chc.2005.08.007_bib188","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00004583-199804000-00015","article-title":"Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents","volume":"37","author":"Kumra","year":"1998","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"10","key":"10.1016\/j.chc.2005.08.007_bib189","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1097\/01.chi.0000171904.23947.54","article-title":"Hematological adverse events in clozapine-treated children and adolescents","volume":"44","author":"Gerbino-Rosen","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"}],"container-title":["Child and Adolescent Psychiatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056499305000726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056499305000726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T22:35:53Z","timestamp":1760999753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056499305000726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":189,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["S1056499305000726"],"URL":"https:\/\/doi.org\/10.1016\/j.chc.2005.08.007","relation":{},"ISSN":["1056-4993"],"issn-type":[{"value":"1056-4993","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recognizing and Monitoring Adverse Events of Second-Generation Antipsychotics in Children and Adolescents","name":"articletitle","label":"Article Title"},{"value":"Child and Adolescent Psychiatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chc.2005.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}